Baseline IVUS determined unacceptable

Patients requiring treatment with disallowed study medications

Patients with clinically significant heart disease

Previous or current diagnosis of heart failure (NYHA Class IV) or a documented left ventricular ejection fraction of \< 25%

Patients requiring treatment with any 2 of the following classes of medication at Visit 1 or Visit 2:

* Angiotensin converting enzyme inhibitors

* Angiotensin receptor blockers

* aldosterone receptor blockers or a direct renin inhibitor.

Other conditions may apply

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients